SCHEMBL5539351

SCHEMBL5539351

[c]1cccc2nc(-c3ccsc3)[nH]c12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.39
PDGFRA P16234 1/20 0.39
WNT3A P56704 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
BCHE P06276 1/20 0.35
CYP2A6 P11509 2/20 0.35
CYP2B6 P20813 2/20 0.35
CYP2E1 P05181 1/20 0.35
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
PKN1 Q16512 1/20 0.35
PKN2 Q16513 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C19 P33261 2/20 0.35
CDK5 Q00535 2/20 0.35
CDK5R1 Q15078 2/20 0.35
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694946 0.81 PKN1 (0.56) KDM4EALDH1A1PKN1PKN2NPC1
SCHEMBL694986 0.80 NPC1 (0.55) TNKS2KDM4EALDH1A1PKN1PKN2
SCHEMBL9030999 0.76 NPC1 (0.62) KDM4EALDH1A1PKN1PKN2NPC1
SCHEMBL5541674 0.75 ALDH1A1 (0.58) KDM4EALDH1A1NPC1RAB9ACYP3A4
SCHEMBL5541731 0.75 DHODH (0.39) PDGFRBPDGFRAWNT3ATNKS2BCHE
SCHEMBL694652 0.73 NPBWR1 (0.46) KDM4EALDH1A1CYP3A4TP53GAA
SCHEMBL5542508 0.71 ALDH1A1 (0.37) WNT3ATNKS2KDM4EALDH1A1PKN1
SCHEMBL5543777 0.71 KDM4E (0.37) WNT3ATNKS2KDM4EALDH1A1PKN1
SCHEMBL28830672 0.71 TNKS (0.69) WNT3ATNKS2KDM4EALDH1A1NPC1
SCHEMBL694892 0.69 ALOX5 (0.48) KDM4EALDH1A1NPC1RAB9ACDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-102532162-A 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2012-07-04 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PDGFRB 4062/4885PDGFRA 4209/4885WNT3A 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.